Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors Abstract #2161

Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Aim(s): Surgical resection, ablation, embolization, or radiation, can control discrete sites of progression, allowing patients to continue their existing therapy, and sparing them toxicities of a new systemic treatment.
Materials and methods: We reviewed records to identify patients seen between 1/2014 and 5/2017 with metastatic GEP-NETs who underwent local treatment for focal progression. Patients undergoing lobar HAE or cytoreductive hepatic surgery were not included. The primary endpoint was time to new systemic therapy. Secondary endpoints included time to any additional intervention, PFS, and side effects of treatment.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Taymeyah Al-Toubah

To read results and conclusion, please login ...

Further abstracts you may be interested in

#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#399 Malignant Carotid Body Tumors (CBTs), Clinical Presentation, Investigations and Their Management
Introduction: Malignant CBTs are rare (incidence 0.012%) and their management is not well settled. We present 2 pts. with malignant CBTs to define their presentation, investigations done and treatment undertaken w/ FU.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors: Ahmed M, Tuli M, Alsugair A, AlHindi H, ...
#552 Outcomes After Liver Resection and Multidisciplinary Management of Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
Introduction: Metastatic liver disease from neuroendocrine tumors (mNETs) has a significant impact on prognosis. Although complete surgical resection remains the only potentially curative therapy, a multimodal approach is becoming the standard by which it is managed.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Douglas Quan
Authors: Fehr A, Bhatia P, Kocha W, Reid R, ...